Inhibiting HIF-2alpha from the inside out
Nature Chemical Biology
February 25, 2013
A small-molecule inhibitor for the potential cancer target HIF-2alpha is reported in a study published this week in Nature Chemical Biology. This compound should enable scientists to determine whether targeting HIF-2alpha is a viable therapeutic strategy in cancer.
HIF-2alpha in combination with its partner ARNT controls gene-expression changes under the low oxygen conditions-called hypoxia-that exist in many cancerous tumors. The genes expressed in response to HIF-2alpha allow cells to adapt to these stressful conditions and may be an important mechanism allowing tumor cells to survive.
Rick Bruick, Kevin Gardner and colleagues report that a small-molecule inhibitor of HIF-2alpha that binds selectively to a cavity inside of this protein, but not to other related proteins such as HIF-1alpha, disrupts the interaction between HIF-2alpha and ARNT. Disruption of this interaction blocks the ability of HIF-2alpha to impact cellular gene expression and also a cell’s response to oxygen stress.
doi: 10.1038/nchembio.1185
Research highlights
-
Jan 13
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
-
Dec 23
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications
-
Dec 21
Epidemiology: Underdetection of COVID-19 after the first lockdown in FranceNature
-
Dec 18
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
-
Dec 17
Epidemiology: Mapping gaps in measles vaccination coverageNature
-
Dec 17
Neuroscience: When you’re smiling, the whole world smiles with youNature
